Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1KT
|
|||
| Drug Name |
Azetidine urea derivative 2
|
|||
| Synonyms |
PMID26413912-Compound-50
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
JANSSEN PHARMACEUTICA NV BREITENBUCHER, Guy, J. TICHENOR, Mark, S. MERIT, Jeffrey, E. HAWRYLUK, Natalie, A. CHAMBERS, Alison, L. KEITH, John, M
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H22ClN5O3
|
|||
| Canonical SMILES |
C1C(CN1C(=O)NC2=CN=C3N2N=CC=C3)CCOC4=CC(=CC=C4)OC5=CC=C(C=C5)Cl
|
|||
| InChI |
1S/C24H22ClN5O3/c25-18-6-8-19(9-7-18)33-21-4-1-3-20(13-21)32-12-10-17-15-29(16-17)24(31)28-23-14-26-22-5-2-11-27-30(22)23/h1-9,11,13-14,17H,10,12,15-16H2,(H,28,31)
|
|||
| InChIKey |
DUGFOZRFNIVGIA-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Fatty acid amide hydrolase (FAAH) | Target's Patent Info | [1] | |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.